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Abstract
Chimaerins are GTPase-activating proteins that inactivate the GTP-hydrolase Rac1 in a
diacylglycerol-dependent manner. To date, the study of chimaerins has been done mostly in neuronal
cells. Here, we show that α2- and β2-chimaerin are expressed at different levels in T-cells and that
they participate in T-cell receptor signaling. In agreement with this, we have observed that α2- and
β2-chimaerins translocate to the T-cell/B-cell immune synapse and, using both gain- and loss-of-
function approaches, demonstrated that their catalytic activity is important for the inhibition of the
T-cell receptor- and Vav1-dependent stimulation of the transcriptional factor NF-AT. Mutagenesis-
based approaches have revealed the molecular determinants that contribute to the biological program
of chimaerins during T-cell responses. Unexpectedly, we have found that the translocation of
chimaerins to the T-cell/B-cell immune synapse does not rely on the canonical binding of
diacylglycerol to the C1 region of these GTPase-activating proteins. Taken together, these results
identify chimaerins as candidates for the downmodulation of Rac1 in T-lymphocytes and, in addition,
uncover a novel regulatory mechanism that mediates their activation in T-cells.
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INTRODUCTION
T-cell receptor (TCR) engagement triggers a complex series of intracellular signaling steps
that are essential for proper T-cell development and function [1,2]. This cascade of molecular
events is initiated by the antigen-dependent activation of protein tyrosine kinases that, upon
phosphorylation of downstream elements such as Vav1, phospholipase C-γ1 and phosphatidyl-
inositol 3-kinase, promote the activation of multiple biological responses [1,2]. One of these
responses is the assembly of the actin cytoskeleton, a process critical for the formation of stable
immune synapses between the T-cell and the antigen presenting cell, the polarized secretion
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of cytokines, the translocation of a subset of signal transduction molecules to the plasma
membrane, and other T-cell responses [3-5].
The essential role of members of the Rac GTPase family (Rac1, Rac2, Rac3 and RhoG) in the
regulation of F-actin dynamics is now well established in different cell types [6-10]. In the case
of T-cells, Rac1 and Rac2 have been shown to participate in a variety of cell functions,
including synapse and lipid raft formation, antigen- and chemokine-triggered polarization, the
activation of phospholipase C-γ1, the proper stimulation of the Ras GDP releasing factor 1
(RasGRP1)/Ras/Erk pathway, and the upregulation of the activity of the nuclear factor of
activated T-cells (NF-AT) [7,8,10,11]. The analysis of both rac2 knockout animals and Rac1-
overexpressing transgenic mice in the T-cell compartment has also provided strong genetic
evidence supporting the crucial role of these GTPases in T-cell development, T-cell selection,
in the assembly of immune responses to antigens by mature T-lymphocytes, and in the
differentiation of helper T-cells [7,10,11]. Although much less characterized, there is also
information regarding the participation of RhoG in the regulation of the cytoskeleton and NF-
AT activities in T-cells [12]. However, rhoG deficient mice show no major alterations in T-
cell biology [13]. Rac proteins also play roles at the level of antigen presenting cells, since the
combined deletion of rac1 and rac2 genes impairs the antigen-presenting activity of dendritic
cells in mice [10,14].
Like most GTPases of the Ras superfamily, Rac proteins cycle between an inactive, GDP-
bound state and an active, GTP-bound state [9]. During cell stimulation, the transition from
the inactive to the active state is promoted by GDP/GTP exchange factors (GEFs), a group of
enzymes that catalyze the exchange of GDP by GTP on Rac proteins [15-17]. At the end of
the signaling cycle, Rac proteins move back to the inactive state by hydrolyzing the bound
GTP, a step facilitated by the elevation of their intrinsic GTPase activities by GTPase activating
proteins (GAPs) [17,18]. The activity of Rac proteins is also modulated by Rho GDP
dissociation inhibitors (RhoGDIs), a third group of molecules implicated in extracting Rac
proteins from membranes and keeping them sequestered in the cytosol in the GDP-bound state
[19,20]. The importance of this regulatory cycle is demonstrated by observations showing that
mutations on Rac proteins that impair any of those regulatory steps promote the formation of
either dominant negative or constitutively active proteins that severely disrupt Rac-dependent
responses. Likewise, the abnormal upregulation of GEFs or loss of GAP activity has been
associated to drastic developmental and functional dysfunctions in different tissues and species
[21-25].
While the function of RhoGDIs and Rac GEFs has been extensively studied in T-cells using
both signaling and knockout mouse approaches [7,19,26], the analysis of the implication of
Rho/Rac GAPs in T-cell-related functions has remained largely unexplored. To start tackling
this issue, we decided to investigate the implication of a group of Rac-specific GAPs, the
chimaerin family, in TCR signaling. This family is composed of four members in mammals
(referred to as α1-, α2-, β1- and β2-chimaerin) that originate from differential splicing events
of two loci, chn1 (in the case of the α-chimaerins) and chn2 (in the case of the β-chimaerins)
[27-31]. All protein products of these genes are characterized by the presence of a C-terminal
GAP catalytic domain and a most N-terminal C1 domain that binds diacylglycerol (DAG) and
chemical analogs such as bryostatin or phorbol esters [27-29,32,33]. Previous studies have
shown that the C1 domain is important for the subcellular localization of some of these family
members [34,35]. The α2- and β2-family members have also an N-terminal SH2 domain
involved, presumably, in heteromolecular interactions [31,36-38]. α2-chimerin has been the
focus of recent attention because the it has been found that the spontaneous mouse mutation
miffy maps within the chn1 locus [39]. This mutation, which is reproduced by the knockout of
the chn1 gene [38-40], induces locomotor problems due to corticospinal axon guidance defects.
We hypothesized that the function of chimaerin family members could also extended to the
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downmodulation of TCR signaling since these GAPs are regulated by DAG [28,41], an
intracellular second messenger that plays pleiotropic roles during T-cell signaling [1].
Furthermore, there was a recent report indicating that one member of this family, β2-chimaerin,
plays inhibitory roles in the signaling pathways triggered by the CXCL12 chemokine in T-
lymphocytes [42]. Consistent with our hypothesis, we report here that chimaerin family
members are expressed in Jurkat T-cells, that they localize in the immune synapse, and that
they play inhibitory roles in the context of TCR-mediated signals. In addition, we provide
evidence indicating that the upstream regulation of chimaerins in T-cells occurs via DAG-
independent mechanisms.
MATERIALS AND METHODS
Antibodies and reagents
Mouse monoclonal antibodies to green fluorescent protein and AU5 were obtained from
Covance. The mouse monoclonal antibodies to Rac1 and PKCα were obtained from Upstate
Biotechology and BD Transduction Laboratories, respectively. The rabbit polyclonal
antiserum to the Vav1 DH domain has been described previously [43]. The polyclonal anti-
α2-chimaerin antibodies were a generous gift from Dr. C. Hall (Institute of Neurology, London,
UK). The anti-CD3 mouse monoclonal antibody was from Dako. The anti-TCR CD3ζ 448
antibody has been described previously [44]. Horseradish peroxidase-conjugated secondary
antibodies to rabbit and mouse IgGs were obtained from GE Healthcare. The Cy3-labeled anti-
rabbit IgG antibodies, Alexa Fluor 635-labeled phalloidin, and the fluorescent B-cell tracker
CMAC (7-amino-4-chloromethylcoumarin) were all from Invitrogen/Molecular Probes.
Staphylococcus enterotoxin E was obtained from Toxin Technology. Poly-L-lysine was from
EMD/Biosciences-Calbiochem. γ-globulin was obtained from Sigma.
Plasmids
pXJ40-FLAG-α2-chimaerin was kindly provided by Dr. C. Hall. For the generation of the
enhanced green fluorescent protein-α2-chimaerin-encoding vector (pMJC52), the full-length
chn1 cDNA was excised from pXJ40-FLAG-α2-chimaerin by digestion with Hind III and PstI
and ligated into the Hind III/PstI-linearized pEGFP-C3 vector (Clontech Laboratories). For the
generation of the enhanced green fluorescent protein-α2-GAP-encoding vector, a cDNA
fragment comprising the α2-GAP domain (base pairs 761 to 1390) was amplified by PCR using
the pXJ40-FLAG-α2-chimaerin plasmid as template and subcloned into the pEGFP-C3 vector.
Expression vectors encoding enhanced green fluorescent protein-tagged β2-chimaerin and
mutants were obtained from Dr. M. Kazanietz (University of Pennsylvania Medical School,
Philadelphia, USA). Plasmids encoding enhanced green fluorescent protein-CD3ξ, wild type
Vav1 (pJC11), oncogenic Vav1 (Δ1-66 mutation, pJC12), Rac1 (pCEFL-AU5-Rac1) and
constitutively-active forms (Q61L and F28L mutants) of Rac1 (pCEFL-AU5-Rac1Q61L and
pRMP46) have been already described [45-47]. chn and vav1 cDNA sequences were from
human and mouse origin, respectively. pNF-AT-luc was obtained from Dr. G. Crabtree
(Departments of Developmental Biology and Pathology, Stanford University Medical School,
Stanford, USA). pRL-SV40 was from Promega. The pGEX vector containing the Rac1 binding
domain of PAK1 was provided by Dr. R. Cerione (Cornell University, Ithaca, NY, USA).
Cell culture and DNA transfections
The T-cell Jurkat and lymphoblastoid B-cell Raji cell lines were both cultured at 37 °C in an
humidified 5% CO2 atmosphere in RPMI-1640 supplemented with 10% fetal calf serum plus
100 units/ml of penicillin and streptomycin (Invitrogen-Gibco). For DNA transfections,
exponentially growing Jurkat cells were collected, resuspended in 200 μl of RPMI-1640 to a
final concentration of 2 × 107 cells/ml, and electroporated with the indicated plasmids using a
Gene Pulser II apparatus (250 V, 950 μF; BioRad).
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Quantitative reverse transcription-polynucleotide chain reactions (RT-PCR)
Total RNA from Jurkat cells was extracted using the RNeasy mini kit (Qiagen). Quantitative
RT-PCRs were carried out using the QuantiTect SYBR Green RT-PCR kit (Qiagen) using an
iCycler apparatus (Bio-Rad). Primers for the amplification of the α2-chn1 cDNA were 5′-
GGAGCTACCTCATCCGGGAG-3′ (forward) and 5′-TGTGTCTCTTTCAGGACT
GGCA-3′ (reverse). Primers for the amplification of β2-chn2 cDNA were 5′-
GCAGGCGGATGAG CTTCTT-3′ (forward) and 5′-CTCACCCACAAA GTGTTTCCC-3′
(reverse). The gadph mRNA expression levels in each sample were used as internal control
using 5′-GGTCTTACTCCTTGG AGGCCATGTG-3′ (forward) and 5′-ACCTAAC
TACATCGTTTACATGTT-3′ (reverse) primers. Analysis was carried out in six samples, each
of them tested in triplicate.
Immunoblotting
Equal amounts of total cellular lysates were diluted 1:1 with SDS-PAGE sample buffer and
boiled for 10 min. Lysates were then separated electrophoretically and transferred onto
nitrocellulose filters (Schleicher and Schuell). Membranes were incubated with the
appropriated antibodies and immunoreactive bands visualized using a standard
chemiluminescence detection system (Pierce).
GTP-Rac1 pull-down experiments
Jurkat cells transfected with or without the pMJC52 plasmid for 48 h were disrupted in a lysis
buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100,
5 mM β-glycerophosphate, 1 mM NaF, 100 μM Na2VO4, a mixture of protease inhibitors
(Cømplete, Roche Molecular Biochemicals), and 10 μg of a glutathione S-tranferase (GST)
fusion protein containing the Rac1 binding domain of PAK1. Cell lysates were precleared by
centrifugation at 14,000 rpm for 10 min at 4 °C and then incubated with glutathione-Sepharose
beads (GE Healthcare) for 1 h at 4 °C. After extensive washes, samples were boiled in SDS-
PAGE sample buffer, separated by electrophoresis, and the bound Rac1 proteins detected by
immunoblotting using anti-Rac antibodies. GTP-Rac levels were quantitated using the
Quantity One 1D image analysis software (Bio-Rad).
NF-AT luciferase assays
Exponentially growing Jurkat cells were electroporated with 10 μg of a firefly luciferase
reporter plasmid containing NF-AT sites (pNF-AT-luc), 5 ng of a plasmid (pRL-SV40)
encoding the Renilla luciferase, and the appropriate combination of expression plasmids
encoding enhanced green fluorescent fusion molecules̃ when appropriate, 20 μg of pJC11 was
included in the transfections. The total amount of transfected DNA was kept constant in all
transfections by supplementing them with pEGFP-C3. 48 h after transfection, cells were either
left resting or stimulated with anti-CD3 antibodies (10 μg/ml) for 8 h. Cells were then harvested
and luciferase activities determined using the Dual Luciferase Reporter System (Promega)
according to the supplier’s instructions. The values of firefly luciferase activity obtained in the
different samples were always normalized taking into account the activity of the Renilla
luciferase obtained in each sample. To confirm comparable expression of proteins in all
samples, aliquots of lysates were subjected to SDS-PAGE and immunoblotted with either anti-
green fluorescent protein or anti-Vav1 antibodies.
RNA interference
siRNAs to the chn1 mRNA were purchased from Dharmacon. The siRNA sequences utilized
were 5′-CCAAGGCAG CAGAAUACAUdTdT-3′ (sense strand) and 5′-A
UGUAUUCUGCUGCCUUGGdTdT-3′ (antisense strand). As a control, a scrambled siRNA
was used in parallel transfections. To introduce the siRNAs in Jurkat cells, exponentially
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growing cultures were collected, resuspended in 200 μl of RPMI-1640 to a final concentration
of 2 × 107 cells/ml, and electroporated with 5 nmol of the appropriate siRNA in the Gene Pulser
II apparatus as indicated above. NF-AT activation was performed 48 h after the siRNA
transfection, as indicated in previous sections.
Confocal microscopy
For subcellular localization studies, Jurkat cells were transfected with enhanced green
fluorescent protein-chimaerin encoding vectors. 24 h after transfection, cells were transferred
to poly-L-lysine-coated coverslips and allowed to attach for 15 min. Cells were then stimulated
with either an anti-CD3 antibody (10 μg/ml) or phorbol myristate acetate (PMA) (2 μM, Sigma)
for the indicated times, fixed with 3.7% formaldehyde, and analyzed using a laser scanning
confocal microscope (LSM 510, Zeiss). Confocal images were collected using the LSM510
software (Zeiss) and finally processed for the preparation of Figures using the Photoshop
software (Adobe Systems).
Subcellular fractionation studies
Jurkat cells were treated with 2 μM PMA for 5 min, harvested, resuspended in a hypotonic
lysis buffer (20 mM Tris-HCl (pH 7.5), 5 mM EGTA, 1 mM NaF, 100 μM Na2VO4 and the
Cømplete protease inhibitor cocktail) and sonicated. Cell homogenates were subjected to
ultracentrifugation to obtain the soluble (cytosolic-enriched) and particulate (membrane-
enriched) fractions, as previously described [33]. Equal amounts of protein of each of those
fractions were subjected to SDS/PAGE, transferred to nitrocellulose membranes, and
immunoblotted.
Conjugate formation and time-lapse fluorescence microscopy
Jurkat cells were transiently transfected by electroporation with the chn cDNAs 16 h before
being used. Raji cells were loaded at 37 °C for 30 min with CMAC (5 μM), washed,
resuspended in RPMI-1640 supplemented with 5 % fetal calf serum, and preloaded with
Staphylococcus enterotoxin E (1 μg/ml) for 30 min at 37 °C. To allow the formation of T-cell/
B-cell conjugates, the transfected Jurkat cells (2 × 105 cells/slide) were mixed with an equal
number of those Raji cells in a final volume of 50 μl/slide. Conjugates were obtained by low
speed centrifugation, resuspended, and allowed to settle for 15 min at room temperature onto
poly-L-lysine-coated coverslips. Attached cells were fixed for 5 min in 2% paraformaldehyde
in phosphate-buffered saline solution and then permeabilized for 1 min in the same buffer
containing 1% Triton X-100. After blocking Fc receptors with γ-globulin (100 μg/ml), TCRs
were stained serially with anti-TCR CD3ζ 448 and Cy3-labeled anti-rabbit IgG antibodies. F-
actin was also stained using Alexa Fluor 635 phalloidin. Quantitative analysis of conjugates
containing enhanced green fluorescent protein proteins at the immune synapse was assessed
by fluorescence microscopy. In these experiments, we counted at least 125 different conjugates
containing enhanced green fluorescent protein-positive T-cells from three independent
experiments. For time-lapse microscopy, glass bottom culture plates (Mat-Tek) were coated
with fibronectin (20 μg/ml) for 20 h at 4 °C and then saturated with Hank’s balanced salt
solution containing 1% BSA for 30 min at 37 °C. Plates were washed with Hank’s balanced
salt solution and placed onto the microscope stage. 15 × 104 transiently transfected Jurkat cells
resuspended in 1 ml of Hank’s balanced salt solution containing 2% fetal calf serum were
subsequently allowed to attach for 30 min at 37 °C. Staphylococcus enterotoxin E-loaded, red
fluorescent protein-expressing Raji cells (1 × 105) were added to the plate containing the Jurkat
cells and conjugate formation monitored by collecting pictures of the cultures every 60 sec
using an inverted Axiovert 2000 microscope.
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Statistical analysis
When three or more than three groups were analyzed, the statistical significance of the results
obtained was determined by ANOVA analysis followed by a Bonferroni’s multiple comparison
test. When data from only two independent experiments were considered, data were analyzed
using the Student’s t-test. P values ≤ 0.05 were always considered as statistically significant
and indicated as such in the histograms shown in the Figures.
RESULTS
Expression of chimaerin family members in Jurkat T-cells
A previous work reported the expression of the chn2 mRNA in Jurkat and other lymphoid cell
lines [42]. In order to identify whether other family members are expressed in T-cells, we
decided to compare the levels of expression of the chn1 and chn2 mRNAs in Jurkat cells using
quantitative RT-PCR. This analysis confirmed the expression of the chn2 mRNA in this cell
line (Fig. 1A). However, it also revealed that the chn1 transcript levels were ≈60 fold higher
than those of its family counterpart (Fig. 1A). Notably, chn1 mRNA levels were only 2-fold
lower than those of the gadph housekeeping gene (Fig. 1A), indicating that they were relatively
abundant within Jurkat cells. The analysis of the RT-PCR fragments obtained with the chn1-
and chn2-specific primers by agarose gel electrophoresis confirmed that they had the expected
sizes (Fig. 1B). Immunoblot analysis confirmed the expression of α2-chimaerin in these cells
(see below, Fig. 3B).
To verify that α2-chimaerin was active in this cell setting, we performed pull-down experiments
to investigate the effects of an enhanced green fluorescent protein (EGFP)-tagged version of
this GAP in the levels of active Rac1 present in Jurkat cells. As shown in Fig. 1B, the levels
of GTP-Rac1 in TCR-stimulated cells were drastically reduced in cells expressing the EGFP-
α2-chimaerin. These results indicate that α2-chimaerin works as a bona-fide Rac1 GAP in
Jurkat cells.
Negative modulation of CD3- and Vav1-dependent NF-AT activity by chimaerins in Jurkat
cells
To further characterize the implication of chimaerins in the modulation of TCR signals, we
decided to use both gain- and loss-of-function approaches to test the roles of these GAPs in
the modulation of NF-AT, a signaling route activated by the TCR that is crucial for both T-
cell activation and differentiation [48]. To this end, we first used luciferase reporter assays to
test the effect of overexpressing α2- and β2-chimaerin in the levels of NF-AT activity of Jurkat
cells. As shown in Fig. 2A, the overexpression of any of these two chimaerin family members
resulted in a significant reduction of the NF-AT activity induced by the stimulation of Jurkat
cells with soluble anti-CD3 antibodies. Since the activation of NF-AT in Jurkat cells requires
the activity of the Rho/Rac exchange factor Vav1 [49], we also studied the effect of the
overexpression of chimaerins in the activation of NF-AT mediated by the ectopic expression
of this GEF. As initially reported [49], Vav1 overexpression promoted the stimulation of the
transcriptional activity of NF-AT, both in non-stimulated and anti-CD3-stimulated cells (Fig.
2B). Such activity was severely repressed upon the co-expression of either α2- or β2-chimaerin
with Vav1 in Jurkat cells (Fig. 2B). These repressions were not due to improper expression of
the ectopic proteins, because immunoblot analysis indicated that all proteins used in the
experiments had similar levels of expression among different transfections (Fig. 2A,B; insets).
These results indicate that, at least under overexpression conditions, chimaerin family members
have negative regulatory roles in the regulation of the TCR- and Vav1-mediated pathways that
lead to NF-AT activation.
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To corroborate these results under more physiological conditions, we decided to perform loss-
of-function studies to evaluate the specific role of α2-chimaerin in this signaling route. To this
end, we evaluated the levels of NF-AT activity in Jurkat cells in which the expression of both
the chn1 mRNA and α2-chimaerin protein, but not of the chn2 transcripts, were lowered ≈60%
using siRNA-mediated techniques (Fig. 3A,B). As negative control, we measured the NF-AT
activity in Jurkat cells electroporated with a scrambled siRNA. Luciferase-based NF-AT
reporter assays indicated that the chn1 knockdown induced a 3-fold increase in the basal levels
of NF-AT activity of non-stimulated Jurkat cells (Fig. 3C). Likewise, the reduction of α2-
chimaerin expression induced a 2-fold increase in the levels of NF-AT activity of anti-CD3-
stimulated Jurkat cells (Fig. 3C). Taken together, these results indicated that α2-chimaerin does
modulate negatively specific output signals from the TCR.
The GAP activity of chimaerins is required for the inhibition of NF-AT signaling
We next used a collection of β2-chimerin mutants already available in our laboratory to
investigate the role of its three known structural domains in the regulation of NF-AT activity.
This collection included either missense or small intradomain deletions mutants with inactive
SH2, C1 or GAP domains (Fig. 4A, proteins labeled as 2, 3 and 4, respectively) and truncated
mutants lacking the SH2-C1 region, the entire SH2 domain plus downstream sequences, or the
GAP domain (Fig. 4A, proteins labeled as 5, 6 and 7, respectively). In addition, we included
an α2-chimerin mutant containing exclusively the catalytic GAP domain. To facilitate the read-
out of these experiments, we measured NF-AT activities always in the presence of
overexpressed Vav1 because, under these conditions, the levels of NF-AT activity were more
robust than in non-transfected, TCR-stimulated cells (see Figs. 2 and 4B). These experiments
indicated that the β2-chimaerin SH2 region was totally dispensable for the inhibitory activity
of this protein (Fig. 4B, left panel, compare proteins 2, 5 and 6 with protein 1). In contrast, the
GAP domain was essential for the downmodulation of NF-AT signals, since β2-chimaerin
proteins lacking this domain were totally inactive in this cellular response (Fig. 4B, left panel,
compare proteins 4 and 7 with 1). In agreement to these results, the activity of a β2-chimaerin
mutant protein containing only the GAP domain was indistinguishable from that of its wild
type counterpart (Fig. 4B, left panel, compare proteins 5 and 1). Similar results were obtained
when an analogous α2-chimerin mutant was included in the experiments (Fig. 4C, left panel).
Interestingly, the deletion of the entire β2-chimaerin GAP domain seemed to generate dominant
negative mutants, since the levels of NF-AT activity in Jurkat cells were significantly increased
when Vav1 was co-expressed with a C-terminally truncated β2-chimaerin containing
exclusively the SH2-C1 domains (Fig. 4B, left panel, compare bars of protein 7 with the bars
of Vav1 alone). However, this effect was not observed with β2-chimerin mutants containing
small deletions inside the GAP region (Fig. 4B, left panel, protein 4), a discrepancy probably
due to the lower levels of expression of the latter mutant when compared to the β2-chimerin
lacking the entire GAP region (Fig. 4B, right panel, compare lanes 4 and 7).
Whereas the analysis of the SH2 and GAP domains gave a clear-cut picture in all these
experiments, we observed that the role of the C1 domain was more complex. Thus, we found
that the mutation of this domain decreased, although it did not abolish, the biological activity
of the full-length β2-chimaerin protein (Fig. 4B, left panel, compare proteins 3 and 1).
However, we observed that the activity of the isolated GAP domain was similar with or without
an attached C1 region (Fig. 4B, left panel, compare proteins 5 and 6), indicating that the C1
region was totally dispensable for the activity of the N-terminally truncated β2-chimaerin
proteins. Immunoblot analysis confirmed that all these proteins were properly expressed in all
these experiments (Fig. 4B,C, right panels).
To confirm that the downmodulation of the NF-AT pathway by chimaerins is mediated by their
GAP activities and, consequently, relies on the reduction in the levels of active, GTP-loaded
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Rac1 in Jurkat cells, we analyzed the effect of the overexpression of chimerins in the NF-AT
activity triggered by constitutively active versions of Rac1. To this end, we co-transfected
chimaerins with Rac1Q61L, a commonly used GTPase-deficient mutant or, alternatively, with
Rac1F28L, a protein that shows an accelerated rate of nucleotide exchange and, thereby, is
preferentially loaded with GTP. However, unlike Rac1Q61L, this mutant maintains its GTPase
activity intact [50,51]. As shown in Supplementary Fig. S1, α2 and β2-chimerins were
uncapable of dowmodulating the NF-AT activity elicited by the GTPase-deficient Rac1
mutant. Instead, they showed a significant, although not complete inhibition of the NF-AT
activity induced by the rapid cycling Rac1 mutant. Taken together, these results indicate that
the downmodulation of the NF-AT pathway by chimaerins is mediated by its GAP domain
and, consequently, relies on the catalysis of GTP hydrolysis on active Rac1.
Chimaerin proteins do not translocate to the plasma membrane upon TCR engagement
We next investigated the mechanism of regulation of chimaerins during TCR signaling.
Previous works have shown that the upregulation of the activity of chimaerins during signal
transduction occurs concurrently with their shuttling from the cytosol to either the Golgi
apparatus or the plasma membrane. This translocation occurs through the binding of the
chimaerin C1 domain to DAG and, in the case of the Golgi apparatus, on the additional binding
of β2-chimaerin to the Golgi-localized Timp21-I protein [34,35,37]. To study whether a similar
regulation occurred in T-cells, we monitored the changes in the subcellular localization of
EGFP-tagged α2- and β□-chimaerin upon the treatment of Jurkat cells with anti-CD3
antibodies for 5 min. As positive control, we used an EGFP fused to RasGRP1, a DAG-
dependent GEF for Ras that has been shown before to translocate to the plasma membrane of
lymphocytes upon similar stimulation conditions [52,53]. Unexpectedly, we found that the
stimulation of the TCR did not induce any translocation of chimaerin family members to
membrane structures (Fig 5A, see first and second rows of panels from top). Similar results
were obtained when Jurkat cells were stimulated during shorter and longer incubation times
with anti-CD3 antibodies (data not shown). In contrast, the EGFP-RasGRP1 fusion protein
readily moved to the plasma membrane of stimulated Jurkat cells under identical experimental
conditions (Fig. 5A, lower panels).
Since high doses of the DAG analog PMA can also trigger changes in the intracellular
distribution of β2-chimaerin [33,34], we decided to monitor the effect of this compound on the
subcellular localization of α2-chimaerin, β2-chimaerin and RasGRP1. As expected [33,34,
42,54], EGFP-β2-chimaerin and, to a larger extent, EGFP-RasGRP1 redistributed from the
cytoplasm to the plasma membrane upon the administration of PMA to Jurkat cells (Fig 5B,
middle and bottom panels, respectively). By contrast, EGFP-α2-chimaerin kept its cytosolic
localization under the same experimental conditions (Fig. 5B, upper panels). To eliminate the
possibility that the defective translocation of α2-chimaerin was due to either the fusion of the
N-terminal EGFP or to the overexpression conditions, we analyzed the behavior of the
endogenous protein using subcellular fractionation and immunoblotting techniques. As
positive control, we used in these experiments protein kinase C (PKC) α, a protein previously
shown to undergo shifts from the cytoplasm to the plasma membrane upon treatment of T-cells
with phorbol esters [55]. Under conditions in which the endogenous PKCα effectively
translocated to particulate fractions (Fig. 5C, compare middle and bottom immunoblots in the
right column), the subcellular distribution of α2-chimaerin remained unchanged between non-
stimulated and PMA-stimulated cells (Fig 5C, compare middle and bottom immunoblots in
the left column). Taken together, these observations indicate that chimaerins, unlike other C1-
containing proteins such as RasGRP1 and PKCs, do not translocate to the plasma membrane
upon TCR stimulation. In addition, they indicate that the role of the C1 domain in the regulation
of the biological activity of full-length chimaerin proteins shown previously in Fig. 4B does
not relies in its ability to tether these proteins to specific subcellular compartments.
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Recruitment of chimaerins to the T-cell/B-cell immune synapse
Based on these above observations, we decided to monitor whether the subcellular localization
of chimaerins could be influenced by the formation of the immune synapse between Jurkat
cells and superantigen-loaded Raji cells. Using time-lapse fluorescence microscopy, we
observed that both the EGFP-α2- and EGFP-β2-chimaerin proteins were evenly distributed in
the cytosol of non-stimulated T-cells (Fig. 6A, left panels). However, unlike the case of the
stimulation with soluble anti-CD3 antibodies (see above), these proteins rapidly moved to the
immune synapse upon the initial Jurkat cell/B-cell contact (Fig. 6A, third panels from left).
The localization of the EGFP-chimaerin proteins at the immune synapse was maintained for
at least 10-15 min after the first contact (Fig. 6A). This translocation was specific, since the
non-chimeric EGFP did not undergo such changes under identical experimental conditions
(data not shown, but see below, Fig. 6B,C).
To characterize the translocation of EGFP-tagged chimaerins to the immune synapse in more
detail, we resorted to confocal microscopy experiments using formaldehyde-fixed T-cell/B-
cell conjugates (see Materials and Methods). As negative and positive controls, we used Jurkat
cells expressing EGFP alone and a CD3ζ-EGFP fusion protein, respectively. Since the latter
protein is associated to the TCR, it is a good marker to follow up the clusterization of this
antigen receptor upon the recognition of the antigen presenting cell. After transfection of the
appropriate EGFPs and conjugate formation with superantigen-loaded Raji cells, cells were
fixed and stained with anti-CD3ζ antibodies and Alexa Fluor 635-labeled phalloidin to track
the localization of the CD3ζ subunit and F-actin in the immune synapse, respectively. As a
complementary approach, we also measured the distribution of the fluorescence intensity of
each protein along a defined axis of the T-cell in order to obtain a more quantitative view of
the translocation of both the EGFPs and CD3ζ. These experiments indicated that α2- and β2-
chimaerins were detected in the cytosol and the immune synapse of unconjugated and
conjugated T-cells, respectively (Fig. 6B,C; first and second rows of panels from top,
respectively). As expected, the endogenous CD3ζ (data not shown) and the ectopically
expressed CD3ζ-EGFP (Fig. 6B,C, third row of panels) were homogenously distributed in the
plasma membrane of non-engaged T-cells but, upon conjugation, both of them redistributed
preferentially towards the immune synapse (Fig. 6B,C, third row of panels). F-actin was not
detected in non-engaged T-cells but, as in the previous cases, accumulated at the T-cell/B-cell
contact upon conjugate formation (Fig. 6B, see panels in the four column from left). In contrast,
the non-chimeric EGFP molecule remained in the cytosol and the nucleus both in non-
conjugated and conjugated T-cells (Fig. 6B,C; bottom panels).
To measure these translocation events in more detail, we counted the percentage of EGFP-
chimaerin molecules present in the immune synapses of paraformaldehyde fixed T-cell/B-cell
conjugates. As a positive control, we also estimated the percentage of translocation of the TCR
CD3ζ subunit to the same cellular structures in the EGFP-positive cells. These experiments
indicated that 80% of the conjugated T-cell/B-cell complexes showed the EGFP-α2-chimaerin
at the immune synapse, a percentage similar to that shown by CD3ζ molecules Fig. 6D). Similar
(results were obtained with EGFP-β2-chimaerin, although the translocation of this chimaerin
family member was slightly less efficient (59% of all conjugates; Fig. 6D). However, under
these conditions, we also observed that the localization of TCR CD3ζ at the immune synapse
was also reduced to ≈67% of conjugation events (Fig. 6D). In agreement with the previous
results, the non-chimeric EGFP protein showed no migration to the immune synapse (Fig. 6D).
These results indicate that the subcellular localization of chimerins is modulated by the
formation of the immune synapse with antigen presenting cells.
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Structural determinants of the translocation of chimaerins to the T-cell/B-cell immune
synapse
To characterize the molecular determinants responsible for the translocation of chimaerins to
this structure, we investigated the ability of the previously used chimaerin mutant proteins to
translocate to the areas of T-cell/B-cell contact. These experiments indicated that the GAP
region was not required for this translocation event, because β2-chimaerin molecules
containing an inactive GAP domain translocated to the immune synapse at rates similar to those
shown by the wild type protein (Fig. 7A,B, compare first and second panels from top; Fig. 7C).
In concordance with these observations, we observed that the β2- or the α2-chimaerin GAP
domains could not translocate to the immune synapse in the absence of the N-terminal regions
(Fig 7A,B, see third and fourth panels from top, respectively; Fig. 7C). Instead, a truncated
β2-chimaerin protein containing only the N-terminal SH2 and C1 domains did show optimal
anchoring to the immune synapse (Fig. 7A,B, fifth panel from top; Fig. 7C), suggesting that
the SH2, the intervening sequence (ITS) and/or the C1 were involved in this translocation
event. The subsequent analysis of the β2-chimaerin C1 point mutant eliminated the possible
participation of the C1 region in this response, because this protein migrated as efficiently as
its wild type counterpart to the immune synapse (Fig. 7A,B, sixth panel from top; Fig. 7C).
Intriguingly, we also observed that β2-chimaerin proteins carrying a mutation in the SH2
phospho-tyrosine binding pocket could also translocate to the immune synapse (Fig. 7A,B,
seventh panel from top), suggesting that the ITS alone or in combination with some of the other
N-terminal domains contribute to this translocation step (see Discussion). In the absence of T-
cell/B-cell conjugation, the EGFP-chimaerin proteins were visualized exclusively in the
cytosol or, alternatively, both in the cytosol and the nucleous (in the case of the isolated GAP
regions, Fig. 7A, left column). As controls for these experiments, we observed that the
endogenous CD3ζ subunit and F-actin concentrated in the immune synapse in the majority of
the T-cell/B-cell conjugates screened by confocal microscopy (Fig. 7A-C). In contrast, the non-
chimeric EGFP remained in the cytosol and the nucleus both in the non-conjugated and
conjugated cells (Fig. 7A,B, bottom panels). Taken together, these results indicate that the
translocation of chimaerins to the immune synapse is not mediated by the interaction of these
proteins with activated Rac1 (via the GAP region), DAG (via the C1 domain) or other
intracellular phospho-proteins (via the SH2 domain) that could be present at high local
concentrations in the immune synapse.
The differential behavior of chimaerin in terms of membrane translocation between anti-CD3-
stimulated and B-cell-conjugated Jurkat cells indicated that these GAPs may require specific
signals to become physically close to plasma membrane. Given the high content of F-actin in
the immune synapse, we hypothesized that cytoskeletal-dependent signals may contribute to
this translocation event. To explore this possibility, we investigated whether chimaerins could
move to the plasma membrane in non-conjugated cells under conditions of high levels of F-
actin polymeration induced by the expression of the oncogenic, constitutively active version
of Vav1. α2- and β2-chimaerin did translocate to the membrane under these conditions.
However, such translocation was circumscribed to areas of the plasma membrane enriched in
both Vav1 and F-actin molecules (Fig. S2). Taken together, these results suggest that the
effective translocation of chimaerins to the plasma membrane of T-cells requires conditions
that trigger high, or spatially concentrated levels of F-actin polymerization.
DISCUSSION
We have shown in this work that chimaerins participate in the modulation of the signaling
output of the TCR, the receptor of T-cells in charge of T-cell development, T-cell selection,
and antigen recognition [1]. In agreement to this function, we have observed that α2- and β2-
chimaerin migrate to the immune synapse in the Jurkat:Raji-superantigen system. In addition,
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we have shown using both gain- and loss-of-function approaches that chimaerin family
members participate in the downmodulation of TCR- and Vav1-dependent pathways leading
to NF-AT stimulation. The use of chimaerin mutant proteins indicate that their three structural
domains contribute differently to the TCR-related functions of chimaerins and, in addition,
that their importance may vary depending on the type of biological process analyzed. In the
case of NF-AT responses, we observed that the SH2 domain is irrelevant and the GAP region
essential for the effective action of α2- and β2-chimaerin on this route. The function of the C1
domain is more complex, being important for the activity of the full-length protein but totally
dispensable for the N-terminally truncated mutants. While the requirement of the catalytic
domain is fully consistent with the role of chimaerins as Rac1-specific GAPs, the results
obtained with SH2 and C1 mutants can be rationalized taking into consideration the β2-
chimaerin crystal structure [56]. This model indicates that the inactive form of β2-chimaerin
adopts an auto-inhibitory, “closed” conformation in which the C1 and GAP domains are buried
inside the molecule by overlapping sequences of the N-terminus. Due to this, the phospholipid
binding surface of the C1 is not exposed to the exterior of the protein and, in addition, the GAP
region is inactive due to both a catalytically inefficient conformation and the occlusion of the
GTPase binding site [56]. According to this model, the binding of the C1 to DAG, PMA or
other possible ligands would unleash that inhibitory structure, leading to the opening of the
molecule and the exposure of the GAP domain in a catalytically compatible structure [56].
Based on this model, the lack of requirement of the C1 domain for the activity of the mutants
containing the isolated GAP domain observed in our experiments could be explained because,
due to the removal of the inhibitory N-terminal sequences, these mutants are already in a fully
active conformation. Likewise, the regulatory role of the C1 in the case of full-length GAP
proteins would reflect its importance for eliminating the auto-inhibitory structure of these
GAPs during signal transduction. In the same regulatory context, the full activity of the SH2
mutants in NF-AT downmodulation is an indirect confirmation of the passive role of this
domain in the process of chimaerin activation inferred from the crystal structure of these
proteins.
Interestingly, we have observed that chimerins translocate to the immune synapse during TCR
signaling. Using a collection of chimaerin mutants, we have also observed that this tethering
step is C1 independent, suggesting that DAG signaling is not directly involved in this signaling
step. This is not a property that can be generalized to all C1-containing proteins, because PKD1
does require DAG for effective translocation to the immune synapse [57]. However, it should
be noted that the translocation of PKCθ to the immune synapse appears to be cytoskeletal-
dependent rather than DAG-mediated [58,59]. A role of the F-actin cytoskeleton in the
translocation of RasGRP1 to the plasma membrane has been also demonstrated [54]. It is likely
that a similar mechanism may occur in the case of chimaerins, since we have observed that
these GAPs can effectively move to membrane areas under artificial conditions of F-actin
polymerization, both in T-cells (this paper) and non-hematopoeitic cells (i.e., COS1 cells,
unpublished data). The results presented in this work also indicate that the structural motif(s)
involved in the translocation of chimerins to the immune synapse are localized in their N-
terminus. Thus, the isolated GAP domains of either α2- or β2-chimerin do not translocate to
this structure upon T-cell/B-cell conjugation. By contrast, a truncated version of β2-chimerin
encompassing the SH2-ITS-C1 region translocates as efficiently as the wild type protein to the
immune synapse. Several observations indicate that the ITS region is probably involved in this
regulatory step. Thus, we have observed that a β2-chimerin protein containing a mutation in
the SH2 that eliminates its phosphotyrosine binding activity (although not the overall folding
of the domain) still translocates to the immune synapse, suggesting that this tethering step does
not involve a canonical phosphotyrosine-dependent protein-protein interaction event.
Furthermore, we have observed that β1-chimerin, an isoform that lacks the SH2 domain but
contains most of the ITS, also translocates to the immune synapse. However, this translocation
is lost upon the deletion of β1-chimerin ITS (data not shown). Despite this evidence, all our
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efforts aimed at demonstrating that the isolated ITS intervening region translocates to the
immune synapse have yielded negative results. At this moment, we do not know whether this
lack of translocation is due to a technical problem derived from the generation of the EGFP-
ITS (i.e., lack of proper folding) or, alternatively, that is due to the need for cooperating actions
by other domains present in the chimaerin structure. Further studies will be needed to address
this important regulatory issue.
In addition to the DAG-independent translocation of chimerins to the immune synapse, a totally
unexpected result of our work is the observation that α2-chimaerin and β2-chimaerin do not
translocate to the plasma membrane or the Golgi apparatus upon the stimulation of Jurkat cells
with soluble anti-CD3 antibodies. Furthermore, we could not see any translocation of α2-
chimaerin upon treatment of cells with PMA although, in this case, β2-chimaerin did show an
enrichment in the cellular membranes of Jurkat cells. This behavior is in contrast to previous
results in this GAP family in other cell types [34,35,37]. Several observations indicate that the
lack of regulation of chimaerin by DAG in Jurkat cells is not an experimental artifact. Thus,
we have demonstrated that the DAG-regulated RasGRP1 does shift from the cytosol to the
plasma membrane under identical experimental conditions. Using subcellular fractionation
experiments, we have also demonstrated that the endogenous PKCα can move to membrane-
enriched fractions of PMA-stimulated Jurkat cells in the same conditions in which the
endogenous α2-chimaerin fails to do so. These two observations rule out the possibility that
the lack of translocation of these GAPs during anti-CD3-mediated TCR signaling could be due
to the lack of DAG generation or, alternatively, to artifacts derived from the use of
overexpressed proteins. Given that the isolated C1 domains of α2- and β2-chimaerin show
affinities to DAG analogs similar or even higher than C1 domains of PKCs and RasGRP1
[32,33,60], we believe that the differential behavior of these GAPs is probably a reflection of
the high-energy cost required for releasing the auto-inhibitory structure of chimaerins [56].
This interpretation is consistent with the observation that β2-chimaerin requires in vivo ≈100-
fold higher doses of PMA than PKCα for its effective translocation to cellular membranes
[34].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
Expression and GAP activity of chn family genes in Jurkat cells. (A) Left panel, determination
of the expression levels of chn1 and chn2 mRNAs by quantitative RT-PCR in Jurkat T-cells,
as indicated in Materials and Methods. The values represent the percentage of each transcript
relative to the expression levels of the gadph mRNA used as control. Bars and error bars
represent, respectively, the mean ± s.e.m. of all determinations performed (n = 6). Right
panel, analysis by agarose gel electrophoresis of the size of the chn1, chn2 and gadph cDNA
fragments generated in the RT-PCR experiments. ϕX174, a sample of HaeIII-digested ϕ X174
DNA used as molecular size marker. The size of each cDNA fragment is shown in the right.
bp, basepairs. (B) Left panel, effect of α2-chimaerin on the levels of activated, GTP-bound
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Rac1 present in T-cells. Control Jurkat cells or cells expressing EGFP-α2-chimaerin were left
untreated (-) or stimulated (+) with anti-CD3-antibodies and subjected to pull-down
experiments to detect the levels of GTP-bound Rac1 proteins (top panel). As control, aliquots
of the same total cellular lysates were subjected to immunoblot analysis with anti-Rac1 and
anti-EGFP antibodies to visualize the levels of expression of Rac1 (middle panel) and EGFP-
α2-chimaerin (lower panel) in each sample. Chn, chimaerin; PD, pull-down; TCE, total cellular
extract. Right panel, quantification of GTP-Rac1 levels in control and α2-chimaerin-expressing
Jurkat cells. Values are expressed as fold induction vs. control unstimulated cell and represent
the mean ± standard error (n = 3; **, P ≤ 0.01).
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FIGURE 2.
Chimaerin overexpression leads to the downmodulation of the transcriptional activity of NF-
AT stimulated by both the TCR and Vav1. (A) Effect of the ovexpression of chimaerins in
anti-CD3-stimulated NF-AT levels. Jurkat cells expressing the indicated EGFP molecules were
either left non-stimulated or stimulated with anti-CD3 antibodies and NF-AT activities
determined as indicated in Materials and Methods. Results are expressed as fold change respect
to the NF-AT activity present in non-stimulated cells expressing a non-chimeric EGFP (n = 4;
***, P ≤ 0.001). The expression of the EGFP molecules used in one of these experiments was
determined by immunoblot using anti-EGFP antibodies (inset). Similar expression levels were
obtained in the other experiments (data not shown). Arrows indicate the migration of EGFP-
tagged chimaerins (upper panel) and the non-chimeric EGFP (lower panel). (B) Effect of the
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ovexpression of chimaerins in Vav1-stimulated NF-AT levels. Jurkat cells expressing the
indicated EGFP molecules were either left non-stimulated or stimulated with anti-CD3
antibodies and NF-AT activities determined as indicated in Materials and Methods. Results
are expressed as fold change respect to the NF-AT activity present in non-stimulated cells
expressing the non-chimeric EGFP (n = 4; ***, P ≤ 0.001). The expression of the ectopic
molecules used in one of these experiments was determined by immunoblot with appropriate
antibodies (inset). Similar expression levels were obtained in the other experiments (data not
shown). Arrows indicate the migration of EGFP-tagged chimaerins (upper panel), non-
chimeric EGFP (middle panel), and untagged Vav1 (lower panel).
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FIGURE 3.
The endogenous α2-chimaerin contributes to the regulation of the NF-AT route in Jurkat cells.
(A) Effective knockdown of chn1 transcripts using a siRNA approach. Jurkat cells were
electroporated with the indicated siRNAs and, 48 h later, chn1 and chn2 mRNA levels
determined by quantitative RT-PCR. Values represent the variation in transcript levels of each
chn transcript when compared to those observed in Jurkat cells transfected with a scrambled
siRNA. (B) α2-chimaerin protein levels in siRNA-transfected Jurkat cells. Jurkat cells were
transfected as above and, 48 h later, treated (+) or untreated (-) with anti-CD3 antibodies for
8 h. After this period, cells were lysed and total cellular extracts analyzed by immunoblot with
antibodies specific to α2-chimaerin. WB, western blot. (C) Effect of the chn1 knockdown on
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the NF-AT route. Jurkat cells were electroporated with the luciferase reporter plasmids and the
indicated siRNA molecules and subsequently stimulated with anti-CD3 antibodies. NF-AT
activities were then determined in total cell extracts derived from the transfected cells using
the firefly luciferase assay (see Materials and Methods). Values are expressed as fold change
variations of NF-AT activity in the indicated experimental samples when compared to that
displayed by non-stimulated cells that had been transfected with the scrambled siRNA (n = 3;
*, P ≤ 0.05).
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FIGURE 4.
Structural determinants of the inhibitory activity of chimaerins on the NF-AT pathway. (A)
Schematic representation of the β2-chimaerin mutant proteins used in these experiments. A
α2-chimerin mutant analogous to protein 5 is not shown. ITS, intervening sequence. (B) Left
panel, inhibitory activity of β2-chimaerin mutants on the NF-AT route. Non-stimulated and
anti-CD3-stimulated Jurkat cells overexpressing the indicated combinations of chimaerin and
Vav1 proteins were subjected to NF-AT luciferase determinations. Values are expressed as
fold change variations of NF-AT activity in the indicated experimental samples when compared
to that displayed by non-stimulated cells that had been transfected with a vector encoding the
non-chimeric EGFP (n = 3; ***, P ≤ 0.001; **, P ≤ 0.01). Right panel, expression levels of the
ectopically expressed wild type and β2-chimaerin mutants (upper panel), EGFP (middle panel)
and Vav1 (lower panel) obtained in one of these experiments using the indicated antibodies
(right). The migration of the proteins is indicated by arrows on the left. Similar expression
levels were obtained in the other experiments (data not shown). (C) Left panel, inhibitory
activity of the isolated α2-chimaerin GAP domain on the NF-AT route. Non-stimulated and
anti-CD3-stimulated Jurkat cells overexpressing the indicated combinations of Vav1, wild type
chimaerins or isolated chimaerin GAP domains were subjected to NF-AT luciferase
determinations. Values are expressed as fold change variations of NF-AT activity in the
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indicated experimental samples when compared to that displayed by non-stimulated cells that
had been transfected with a vector encoding the non-chimeric EGFP (n = 3; **, P ≤ 0.01).
Right panel, expression levels of the ectopically expressed wild type chimaerin and GAP
domains (first and second panels from top, respectively), EGFP (third panel) and Vav1 (lower
panel) obtained in one of these experiments using the indicated antibodies (right). The
migration of proteins is indicated by arrows on the left. Similar expression levels were obtained
in the rest of experiments (data not shown).
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FIGURE 5.
Subcellular localization of chimaerin family members in Jurkat cells. (A,B) Jurkat cells
electroporated with vectors encoding the indicated EGFP-tagged proteins (left) were cultured
for 24 h, attached to coverslips, stimulated with either anti-CD3 (A) or PMA (B) for 5 min,
fixed, and analyzed by confocal microscopy. Microscopic images of untreated and stimulated
cells are shown in the left and middle panels, respectively. The white lanes shown in the middle
panels highlight the areas of the cells used to measure the distribution of fluorescence intensities
of the indicated EGFP molecules (right panels). Right panels, profiles of the distribution of the
fluorescence intensities for EGFP-α2-chimaerin (A) and EGFP-RasGRP1 (B) along the axis
highlighted in white in the middle panels. NS, non-stimulated. (C) Subcellular distribution of
endogenous α2-chimaerin (left panels) and PKCα (right panels) in normal and PMA-treated
Jurkat cells. Untransfected Jurkat cells were incubated with (+) or without (-) with PMA for 5
min, lysed in a hypotonic buffer, and soluble and particulate fractions obtained as described in
Materials and Methods. Equal amounts of these fractions were then separated
electrophoretically and subjected to immunoblot analysis with the indicated antibodies.
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FIGURE 6.
Recruitment of chimaerins to the immune synapse upon TCR clustering. (A) Changes in the
subcellular distribution of EGFP-tagged α2- (upper panels) and β2-chimaerin (lower panels)
fusion proteins followed in real time during the formation of T-cell/B-cell synapses. Jurkat
cells expressing the indicated proteins were subjected to conjugate formation with red
fluorescent protein-expressing Raji B-cells and analyzed by time-lapse fluorescence
microscopy, as described in Materials and Methods. The 0 time point was set just before the
first contact between the T-cell and the antigen presenting B cell. Representative images taken
from the indicated times after synapse formation (top) are shown. Asterisks indicate the B-
cells involved in the immune synapse with the T-cell. (B) Co-localization of chimaerin proteins
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with TCR components in the immune synapse. Jurkat cells transfected with the indicated EGFP
molecules (left) were incubated with CMAC-labeled Raji cells previously loaded with
superantigen. Conjugates formed were plated onto coverslips, fixed, stained with anti-CD3ζ
antibodies and Alexa Fluor 635-labeled phalloidin, and subjected to confocal fluorescence
microscopy. Images show in green the localization of the EGFP molecules, in red the
distribution of the CD3ζ subunit and in purple the localization of polimerized actin. A merge
of the above images is shown on the right column, where the areas of overlap between EGFP
molecules and CD3ζ are seen as yellow areas. The white arrows shown in the panels of the left
and right columns indicate the cell areas used to measure the distribution of fluorescence
intensities of the indicated EGFP molecules and/or CD3ζ shown in Fig. 6C. (C) Distribution
of intensities corresponding to EGFP (green) and CD3ζ (red) in non-conjugated (left panels)
and conjugated (right panels) Jurkat cells along the areas indicated in Fig. 6B. The bar shown
in the right panels indicates the area of the immune synapse, as assessed by the distribution of
the CD3ζ marker. (D) Quantification of the percentage of localization of the indicated EGFP
molecules in immune synapses, as indicated in Materials and Methods (n = 3, each including
at least 125 independent T-cell/B-cell conjugates expressing each of the indicated chimaerin
constructs). IS, immune synapse.
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FIGURE 7.
Translocation of chimaerins to the immune synapse requires an intact N-terminal domain.
(A) Jurkat cells transfected with either EGFP-wild type β2-chimaerin or the indicated EGFP-
tagged β2- and α2-chimaerin mutants (left). 16 h later, cells were incubated with CMAC-
labeled, superantigen-loaded Raji cells to allow the formation of T-cell/B-cell conjugates.
Conjugates were then plated onto coverslips, fixed, stained with anti-CD3ζ antibodies and
Alexa Fluor 635-labeled phalloidin, and analyzed by confocal fluorescence microscopy.
Images show in green the localization of EGFP-tagged molecules, in red the distribution of the
CD3ζ subunit and in purple the localization of polymerized actin. A merge of the above images
is shown on the right panels, where the areas of overlap between EGFP molecules and CD3ζ
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are seen in yellow color. The white arrows shown in the panels of the right column indicate
the cell areas used to measure the distribution of fluorescence intensities of the indicated EGFP
molecules and/or CD3ζ shown in Fig. 7B. (B) Distribution of the fluorescence intensities
corresponding to EGFP (green) and CD3ζ (red) in conjugated Jurkat cells along the areas
indicated in Fig. 7A. The bar indicates the area of the immune synapse, as assessed by the
distribution of the CD3ζ marker. (C) Quantification of the percentage of localization of the
indicated EGFP molecules in immune synapses, as indicated in Materials and Methods (n = 3,
each including at least 125 independent T-cell/B-cell conjugates expressing each of the
indicated chimaerin constructs).
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